Objective To discuss the clinical effect of urinary kallikrein in the treatment of progressive cerebral infarction and its influence on hs -CRP.Methods 92 patients with progressive cerebral infarction were ran-domly divided into the observation group(n =46)and the control group(n =46)according to the digital table.The control group was treated with conventional therapy,the observation group was treated with urinary kallikrein based on the control group.The clinical effects and the influence on hs -CRP were compared between the two groups.Results The explicit efficiency and the effective rate of the observation group were 71.7% and 89.1%,which were significant-ly higher than 43.5% and 69.6% in the control group(χ2 =7.522 0,5.372 7,P <0.05 or P <0.01).After treat-ment,the hs -CRP levels in the two groups were (11.79 ±3.92)mmol/L and (10.04 ±3.90)mmol/L,which were significantly lower than (13.48 ±3.89)mmol/L and (13.54 ±3.93)mmol/L before the treatment(t =4.287 4, 2.075 5,P <0.05 or P <0.01),and hs -CRP of the observation group was significantly lower than the control group (t =2.146 5,P <0.05).After treatment,NIHSS scores in the two groups were (9.91 ±4.35)points and (6.82 ± 4.32)points,which were significantly lower than (15.39 ±4.34)points and (15.43 ±4.37)points before treatment (t =6.048 6,9.503 2,all P <0.01 ),and NIHSS score of the observation group was significantly better than the control group(t =3.418 5,P <0.01 ).After treatment,the Barthel in the two groups were (53.87 ±18.12)and (68.21 ±18.14),which were significantly higher than (34.35 ±18.08)and (34.42 ±18.11 )before treatment (t =5.172 1,8.943 4,all P <0.01),and Barthel of the observation group was significantly better than the control group(t =3.793 3,P <0.01).There was no obvious adverse reactions and side effects in the treatment.Conclusion Urinary kallikrein can effectively improve the local blood flow perfusion,restore nerve function damage and improve the living ability of the patients in the treatment of progressive cerebral infarction,it has curative effect,and it's safe and reliable,which is worthy of promotion.

Objective To investigate the effect of an oral calcium load on serum electrolytes and PTH concentrations in healthy apheresis donors.Methods Forty-five apheresis donors were divided into two groups: calcium group(11 donors,taking oral calcium before apheresis) and no calcium group(34 donors).Serum parathyroid hormone(PTH),total calcium(Ca),phosphorus(P),potassium(K),sodium(Na) and magnesium(Mg) were measured before and after the apheresis process.Twenty-four whole blood donors served as controls.Results After the apheresis process,PTH concentrations in calcium group and mean P in no calcium group increased significantly(P

Objective To investigate the CT manifestations of inflammatory and tumorous diseases in peritoneum, and to improve the abilities of diagnosis and differential diagnosis. Methods Conventional non-enhanced and enhanced CT were performed in 63 patients. The mean value of peritoneal structures in normal persons and patients were measured and calculated. The CT features of abnormal peritoneum were divided into 5 classes that were collated with their pathological changes. The numbers of each CT class appeared in inflammatory and tumorous diseases were countered. The data were treated with statistical methods for comparing the differences.Results (1) In normal persons, the non-enhanced and enhanced mean CT values were (-88.60?18.30) and (-78.73?16.90) HU, respectively, while in patients, they were(-38.63?15.64) and (-1.42?14.42) HU, respectively. CT value of abnormal peritoneum was significantly higher than that of normal group. (2) There were 183 places of abnormal peritoneum in five classes: firstly, fine and blur attenuation in 65 places (56 inflammations and 9 tumors); secondly, linear or strip thickening of peritoneum in 25 places (12 inflammations and 13 tumors); thirdly, attenuation of disorganized strip and piece or nodus in 50 places (8 inflammations and 42 tumors); fourthly, soft tissue mass in 28 places (5 inflammations and 23 tumors); and fifthly, cake peritoneum in 15 places ((2 inflammations) and 13 tumors). The data showed statistical differences (P

Objective ToevaluatevaluesofADCofDWIinmolecularsubtypeofnonmassenhancedbreastcancerandprovidereference forclinicaltherapeuticplan.Methods Nonmassenhancedbreastcancerincluding46casesofductalcarcinomainsitu(DCIS)and58 casesofinvasiveductalcancer(IDC)wereprovedbyhistopathologyandexperiencedMRIofroutinesequence,DWIanddynamicenhancement.All thepatientsweredividedintobothgroups,DCISgroupandIDCgroup.Accordingtoimmunohistochemicalcharacteristic,molecularsubytpes,Luminal A,LuminalBandnon-Luminalwerefurthergroupedineachgroup.TheADCvaluesoflesionsweremeasuredonADCmapsofb=0s/mm2and b=800s/mm2.TheADCvaluesofnormalbreastgland,DCISandIDC,ofmolecularsubtypeinternaleachgroup,ofsamemolecular subtypebetweengroupswerestatisticallycomparedI.fthedatahadmarkeddifference,ROCcurveofADCvaluesweredrewfortestingtheefficacy diagnosis.Results TheROImeasuredwere104positionsinnormalglands,86inDCISand115inIDCinwhichtheADCwererespectively (1.77±0.27)mm2/s,(1.08±0.14)mm2/sand (0.89±0.15)mm2/sthathadstatisticaldifference.TheADCvaluesofLuminalA, LuminalBandnon-LuminalinDCISwererespectively(11.1±01.5)mm2/s,(1.04±0.13)mm2/sand(1.04±0.13)mm2/sthathadn’tstatistical difference.TheADCvaluesofLuminalA,LuminalBandnon-LuminalinIDCwererespectively(0.95±0.19)mm2/s,(0.87±0.13)mm2/sand (0.84±0.15)mm2/sthathadstatisticaldifference.TheADCvalueshadstatisticaldifferenceinsame molecularsubtypebetween DCISandIDC.InanalysisofROCofIDC,AUCofADCvalueswererespectively0.561,0.632and0.520,theirsensitivity>81%,but specificitywaslower.Conclusion TheADCvaluesofIDCinLuminalA wasmarkedhigherthanLuminalBandADCvaluesofnon-Luminalwaslowest.TheADCvaluesofLuminalA,LuminalBandnon-LuminalinDCISwerehigherthancorrespondingmolecular subtypeofIDCthatmeansADCvaluescouldindicatemolecular subtypeinformationofbreastcancerandprovidereferencefor clinicaltherapeuticplan.

Sudden sensorineural hearing loss (SSNHL) refers to the sudden and unexplained sensorineural hearing loss within 72 h and a decrease in hearing of ≥30 dB affecting at least 3 consecutive frequencies. It is one of the common emergencies in neurology and otolaryngology. Early etiological evaluation and systematic and targeted treatment are very important for delaying the progression of SSNHL and restoring hearing. Recent studies have shown that SSNHL overlaps with vascular risk factors of ischemic stroke, and may predict the risk of ischemic stroke. SSNHL may be one of the clinical manifestation and even the prodromal symptoms of ischemic stroke, especially the infarction of the blood supply area of the anterior inferior cerebellar artery or its branch internal auditory artery. Although these factors can not fully reveal the relationship between SSNHL and ischemic stroke, they are enough to warn clinicians that they should consider the possibility of ischemic stroke when receiving patients with SSNHL. Screening of vascular risk factors for patients with SSNHL as early as possible is helpful to avoid the risk of recurrence of ischemic stroke.